Search

everythinglearnresearchcommunity

for

Search:↓

Hedgehog pathway inhibitors for advanced basal cell carcinoma can cause side effects, but managing them helps maintain treatment.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Aumolertinib effectively controls lung cancer and improves quality of life.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.

LDE225 is a promising skin-applied treatment for basal cell carcinoma with good skin penetration and effectiveness.

Selumetinib significantly reduced tumor size and improved vision in a child with neurofibromatosis type 1.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.

Potassium channel activators like nicotinamide and minoxidil might help treat solid tumors.

AMPK activation may reduce melanoma risk in red-haired individuals.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.

Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

A woman's hair turned white after taking a cancer drug called dasatinib.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.